Anti-DRAK2(CT)Antibody
CatalogNo.:2149
Size:100ugIgGinPBS,pH7.4,purifiedbyimmunoaffinitychromatography.
Certainserine/threonineproteinkinases,suchasASK-1andRIP,aremediatorsofapoptosis.Twonovelserine/threoninekinasesthatinduceapoptosishavebeenidentifiedanddesignatedDRAK1andDRAK2forDAPkinase–relatedapoptosis-inducingproteinkinases.DRAKscontainanN-terminalkinasedomainandaC-terminalregulationdomain.OverexpressionofDRAK2inducesapoptosis.DRAKshavehighsequencehomologytoDAPandZIPkinases,andtheyrepresentanovelfamilyofserine/threoninekinaseswhichmediateapoptosisthroughtheircatalyticactivities.
DRAK2islocatedincellnuclei,andthemRNAforDRAK2isubiquitouslyexpessedinhumantissues.
Antigen:Peptidecorrespondingtoaa351-365ofhumanDRAK2(accessionno.AB011421).
HostSpecies:Rabbit
StABIlizers:None
Preservatives:0.02%sodiumazide.
ThisantibodyrecognizeshumanDRAK2(45kDa).Nocross-reactivitywithDRAK1,DAPorZIPkinases.
APPLICATIONSImmunoblotting:useat1ug/ml.
WesternblotanalysisofDRAK2inJurkat(1,3)andRaji(2,4)celllysateintheabsence(1,2)orpresence(3,4)ofblockingpeptidewithDRAK2antibodyat1g/ml.
NOTE:Theapprox.70kDabandobservedispeptide-blockableandmayrepresentDRAK2complexedwithanotherprotein.
Positivecontrol:WholecelllysatefromJurkatorRajicells.
Immunocytochemistry:useat10ug/ml
ImmunocytochemicalstainingofDRAK2inJurkatcellswithDRAK2antibodyat10μg/ml.
Thesearerecommendedconcentrations.Endusershoulddetermineoptimalconcentrationsortheirapplications.
DiluteinPBSormediumwhichisidenticaltothatusedintheassaysystem.
Thisantibodyisstableforatleastone(1)yearat-20oC.Avoidmultiplefreeze-thawcycles.
Forinvitroinvestigationaluseonly.Notforuseintherapeuticordiagnosticprocedures.
